Clinical Trial Search

Primary: Safety - Adverse Events — 1; 1; 0; 2 Participants

Primary: Baseline-adjusted Cmax of PTH(1-84) — 295.662; 330.820; 175.468; 99.708 Picogram per milliliter (pg/mL)

Primary: Maximum Observed Concentration (Cmax) of UPB-101 — 11.6; 24.4; 35.1; 34.9 ug/mL

Primary: Geometric Mean Fold Rise (GMFR) From Baseline in Antibody Level — 4.4; 0.9 Ratio

Primary: Percentage (%) of Subjects With Drug-related Adverse Events (AEs) — 13.3; 9.1; 36.4; 57.9 Percentage of Participants

Primary: Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs During the Single-Dose (SD) Period — 0; 0; 0; 0 participants

Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 0.0; 0.0; 0.0; 5.6 Percentage of participants

Primary: Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] of Crizotinib — 1423; 3806; 6569 ng*hr/mL

Primary: Maximum Rates of Extensor Digitorum Brevis (EDB) Muscle M-Wave Amplitude Reduction From Baseline — 9.02; 48.53; 70.95; 81.62 Percentage of Reduction

Primary: Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 1 — 7.6; 0.0; 5.9; 0.0 Percentage of participants

Primary: Number of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE) — 1; 0; 2; 1 Participants

Primary: Age-Dependent Change in Striatal 18F-DTBZ Uptake of Healthy Subjects. — 0.05 SUVR

Primary: Number of Participants With Investigator Defined Drug-related Adverse Events — 2; 1; 4; 2 Participants

Primary: SRD Part - Number of Subjects With Drug-related Adverse Events — 0; 0; 0; 0 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs , and TEAEs Leading to Participant Discontinuation From Study — 0; 3; 0; 0…

Primary: Percent Change in Anti-Fxa Activity From Baseline to the End of Infusion (EOI) Nadir. — -94.50; -29.00; -98.00; -37.00 percent change — p=0.0275

Primary: Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve (AUC) of LY2484595 — 12200; 17800; 17800 hours times nanograms per milliliter

Primary: Number of Subjects With Drug-related Adverse Events (AEs) — 0; 0; 0; 0 Participants

Primary: Percentage of Subjects With Drug-related Adverse Events — 22.2; 33.3; 0.0; 0.0 Percentage of subjects

Primary: Number (%) of Subjects With Drug-related Adverse Events — 28.0; 51.9; 33.3; 92.6 Percentage of participants

Primary: Number of Subjects With Drug-Related Adverse Events (AEs) — 1; 0; 0; 0 Participants

Primary: Safety (Physical Examination, Vital Signs, ECG, Haematology, Biochemistry, Urinalysis, Coagulation Factors, Coagulation-related Parameters, Injection Site Tolerability…

Primary: Whole Body Radiation Dosimetry — 0.0186; 0.0132; 0.0179; 0.0157 mSv/MBq

Primary: Fold Change in Long Chain Fatty Acids — 1; 0.76 Fold Change in long chain fatty acids

Primary: Dosing Period 1: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1 — 77.4; 79.5; 256; 259 ng/mL

Primary: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Rosuvastatin, Sildenafil and Furosemide. — 161; 165; 532; 482 ng*h/mL

Primary: Number of Participants With Any Adverse Event (AE) and Serious Adverse Events in Part 1 — 1; 0; 0; 1 Participants

Primary: Number of Participants With Solicited Injection Site and Systemic Adverse Events — 1; 2; 1; 3 participants

Primary: Incidence of Treatment-Emergent Adverse Events — 1; 0; 2; 1 Participants

Primary: Number of Participants Reporting Any Solicited Administration Site Events — 8; 2; 0; 19 Participants